Skip to Main Content

INFORMATION FOR

Facioscapulohumeral Muscular Dystrophy

Facioscapulohumeral muscular dystrophy (FSH) was first described by Landouzy and Dejerine in 1885, and was therefore named after them. Duchenne had published a photograph of a typical FSH patient in 1862, but the disease still became known as Landouzy-Dejerine disease. From the beginning, FSH was recognized as an autosomal dominant disorder. This was confirmed in 1950 by Tyler and Stephens, who conducted a large study based upon records from the Mormon Church in Salt Lake City, Utah.

The exact nature of the disease was a topic of heated debate for many years. The controversy centered around whether the muscle weakness and wasting was primarily from a neuropathic or myopathic cause. The debate was eventually settled in favor of a myopathic etiology, and in 1954 Walston and Nattrass included FSH as one of the three categories of muscular dystrophy, along with Duchenne MD and Limb-Girdle MD. FSH has survived as a distinct clinical entity, which was confirmed by the discovery that it is a distinct, genetic disorder as well.